# US 2013/0157995 A1 · Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157995 A1
- Document ID: US20130157995A1
- Status: Published application
- Kind: A1
- Application number: 13/819,067
- Filed: 2011-09-02
- Published: 2013-06-20
- Earliest claimed: 2010-09-03
- Assignees: University of Florida Research Foundation, Inc.; The Trustees of the University of Pennsylvania
- Inventors: William Reade Kem; Ferenc Soti; Anne Rouchaud; Hong Xing; Jon Lindstrom; Kristin Marie Andrud
- Web page: https://patentgrep.com/patent/US20130157995A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Embodiments of the present disclosure provide for compounds such as those shown in FIG. 1.1 (compounds A, B, C, and D), 2′substituted nicotine compounds, azetidine compounds, ether linked nicotine compounds (FIG. 1.2, compounds E, F, G, and H), methods of synthesis of the compounds, methods of treatment of a condition using compounds A, B, C, D, 2′substituted nicotine compounds, azetidine compounds, or ether linked nicotine compounds, methods of selectively stimulating alpha7 nAChR and/or alpha4beta2 receptors, and the like.

## Claims

### Claim at position 1

1-35. (canceled)

### Claim 36

A compound having the formula:
wherein each of Compounds A-H include R2′ and one of: R4′, R5′, R6′, and R7′, wherein one of R2′, R4′, R5′, R6′, and R7′ is selected from an alkyl group having from 1 to 6 carbons, an alkyl amino group having from 1 to 6 carbons, an alkyl group having a hydroxylic group and having from 1 to 6 carbons, and a methoxy group, wherein the other of R2′, R4′, R5′, R6′, and R7′ is a substituted or unsubstituted group selected from: an aliphatic group, an alkoxy group, a cycloalkyl group, an aryl group, a heteroaryl group, and a heterocyclic group, wherein each of RN1, RP1, RP2, RP3, RP4, RP5, RP6, RP7, and RP8 are independently a substituted or unsubstituted group selected from: an aliphatic group, an alkoxy group, a cycloalkyl group, an aryl group, a heteroaryl group, and a heterocyclic group.

### Claim 37 (depends on 36)

The compound of claim 36, wherein R4′, R5′, R6′, or R7′ is at the trans position.

### Claim 38 (depends on 36)

The compound of claim 36, wherein R4′, R5′, R6′, or R7′ is at the cis position.

### Claim 39 (depends on 36)

The compound of claim 36, wherein the alkyl group in each of the alkyl group, the alkyl amino group, and the alkyl group having a hydroxylic group, has 1 or 2 carbons.

### Claim 40 (depends on 36)

A method, comprising selectively stimulating alpha7 nAChR using R4′, R5′, R6′ or R7′, trans substituted compounds A, B, C, and D and compound E, F, G, and H, respectively, wherein compound A, compound B, compound C, compound D, compound E, compound F, compound G, and compound H are described in claim 36, wherein R4′, R5′, R6′ or R7′ are selected from a group selected from: an alkyl group having from 1 to 6 carbons, an alkyl amino group having from 1 to 6 carbons, an alkyl group having a hydroxylic group and having from 1 to 6 carbons, and a methoxy group.

### Claim 41 (depends on 36)

A method comprising, selectively stimulating alpha7 nAChR and alpha4beta2 receptors using R2′ substituted compound A, compound B, compound C, and compound D, respectively, wherein compound A, compound B, compound C, and compound D, are described in claim 36, wherein R2′ is from a group selected from: an alkyl group having from 1 to 6 carbons, an alkyl amino group having from 1 to 6 carbons, an alkyl group having a hydroxylic group and having from 1 to 6 carbons, and a methoxy group.

### Claim 42 (depends on 36)

A method of treating a condition comprising, administering an effective dose of one or more compounds selected from compound A, compound B, compound C, compound D, compound E, compound F, compound G, and compound H, as described in claim 36, wherein the condition is selected from CNS disorders, treating drug addictions, and inflammatory conditions.
